News

Video

EP. 10: Third-Line OAB Therapies and Patient-Centered Decision-Making

Author(s):

Benjamin M. Brucker, MD,Eman A. Elkadry, MD

Experts provide their perspective on the advent of third-line therapy in OAB and discuss details in the clinical process of transitioning patients out of the second-line setting.

Please see full Prescribing Information for onabotulinumtoxinA, including Boxed Warning.

Sponsored by AbbVie US Medical Affairs

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      This content is intended for US/PR Healthcare Professionals.

      The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.

      Related Videos
      Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
      Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
      Considerations for patient follow-up after onabotA administration
      Considerations for patient follow-up after onabotA administration
      Administering onabotA: Improving patient comfort and easing anxiety
      Administering onabotA: Improving patient comfort and easing anxiety
      Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © - bongkarn - stock.adobe.com
      Experts discuss expanding use of vibegron for OAB
      Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
      Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
      Karyn S. Eilber, MD, answers a question during a Zoom video interview
      Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB
      Woman at doctor | Image Credit: © rocketclips - stock.adobe.com
      Optimizing onabotA for OAB: What are some common misconceptions?
      Closeup of patient with prescription | Image Credit: © gpointstudio - stock.adobe.com
      Investigators characterize vibegron prescribing patterns for OAB
      Colin Goudelocke, MD, answers a question during a Zoom video interview
      Expert outlines advantages of batteryless sacral neuromodulation device
      Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI
      Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI
      Related Content
      Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI
      May 16th 2025

      Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI

      Melissa Kaufman, MD, PhD, FACS Hannah Clarke
      The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.
      Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
      March 21st 2022

      Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

      Urology Times staff
      “This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
      Artificial urinary sphincter for SUI shows safety, efficacy in prospective study
      May 9th 2025

      Artificial urinary sphincter for SUI shows safety, efficacy in prospective study

      Melissa Kaufman, MD, PhD, FACS Hannah Clarke
      "This trial will be the benchmark for research reporting in the future," says Melissa R. Kaufman, MD, PhD, FACS.
      Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
      March 18th 2022

      Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

      Urology Times staff
      “We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
      First patient enrolled in trial of Voro Urologic Scaffold for post-prostatectomy SUI
      April 24th 2025

      First patient enrolled in trial of Voro Urologic Scaffold for post-prostatectomy SUI

      Hannah Clarke
      "What is truly exciting is the potential for this device to meaningfully improve early and long-term continence rates, which can profoundly impact a patient's recovery and overall quality of life,” says Patrick Daily, MD.
      Neuromodulation device shows promising efficacy for neurogenic bladder
      April 16th 2025

      Neuromodulation device shows promising efficacy for neurogenic bladder

      Hannah Clarke
      Data from the pivotal CONTINENCE trial showed encouraging efficacy of SCONE neuromodulation therapy.
      © 2025 MJH Life Sciences

      All rights reserved.